Clinical trials: Rivaroxaban
Healthy
Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects
Rivaroxaban is a direct oral anticoagulant that target specifically activated factor X. Bleeding events related to rivaroxaban are the consequence of physiopathologic, pharmacokinetic issues or poisoning.
- Trial name
- RICHAR (NCT02657512)
- Testing
- rivaroxaban, rivaroxaban and activated charcoal
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Atrial Fibrillation, Stroke
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
The purpose of this study is to compare the efficacy and safety of rivaroxaban with warfarin for the prevention of blood clots in the brain (referred to as stroke) and blood clots in other parts of the body referred to as…
- Conditions
- Atrial Fibrillation, Stroke, Embolism
- Trial name
- NCT00403767
- Testing
- Rivaroxaban, Warfarin
- Where
- 932 sites in United States, Argentina and 42 more
- Volunteers
- 14,269 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Prophylaxis of Venous Thromboembolic Events
Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
The purpose of this study is to evaluate the safety and efficacy of two doses of TB-402 administered as a single intravenous infusion for the prevention of VTE in subjects undergoing total hip replacement surgery.
- Trial name
- NCT01344954
- Testing
- TB-402, Rivaroxaban
- Where
- 36 sites in Austria, Belgium and 7 more
- Volunteers
- 632 people
- Sponsor
- ThromboGenics
Pediatric Venous Thromboembolism
Rivaroxaban in Pediatric Patients With DVT
Prospective interventional randomized controlled trial to assess safety and efficacy of rivaroxaban in pediatric patients with acute deep venous thrombosis.
- Trial name
- NCT07618988
- Testing
- Rivaroxaban, Enoxaparin, Heparin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Blood Loss After a Total Hip Replacement
Blood-sparing During Hip Prosthesis Surgery With Exacyl® in Patients Treated With Rivaroxaban
This study evaluates the efficacy of tranexamic acid versus placebo on perioperative blood loss using two dosage regimens (standard and extended) after a surgery during total hip arthroplasty in patients receiving the novel…
- Trial name
- ESPER (NCT02403596)
- Testing
- Exacyl®
- Where
- 4 sites in France
- Volunteers
- 231 people
- Sponsor
- University Hospital, Brest
Venous Thromboembolism
Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
This study is a retrospective, observational, nationwide population-based cohort study utilizing the South Korea's Health Insurance and Review Assessment Service (HIRA) database.
- Trial name
- NCT05022563
- Testing
- Parenteral anticoagulant, Warfarin, Apixaban
- Where
- 2 sites in South Korea
- Volunteers
- 55,759 people
- Sponsor
- Pfizer
Venous Thromboembolism, covid19
Hemostasis and Inflammation in COVID-19 Patients With Venous and Arterial Thrombotic Complications
The study is aimed at assessing the role of the activity of high-risk markers of thrombotic events (MCP-1, MIP1α, IP-10, phosphatedylserine, calreticulin) on the development of thrombotic complications in patients with COVID -19.
- Conditions
- Venous Thromboembolism, covid19, Thrombosis
- Trial name
- NCT05143567
- Testing
- standard of care anticoagulation in absence of thrombotic complications, standard of care anticoagulation in presence of thrombotic complications, standard of care anticoagulation in combination with elastic compression
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- Ryazan State Medical University
Healthy Volunteers
Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban
The study will address the impact of genetical variation of a protein involved in the intestinal absorption of two new anticoagulants : Dabigatran etexilate and Rivaroxaban.
- Trial name
- DRIVING (NCT01627665)
- Testing
- D->R->C+R, D->R->C+D, R->D->C+D
- Where
- France
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hip Fractures
HIP Fracture Oral thromboPROphylaxis (Hip PRO Pilot)
As our Canadian population ages, hip fractures in these older adults are becoming very common. The best treatment for the majority of these injuries is urgent treatment with surgery.
- Trial name
- HIP PRO Pilot (NCT05775965)
- Testing
- Rivaroxaban 10mg, acetylsalicylic acid (ASA) 81mg Oral Tablet
- Where
- 3 sites in Canada
- Volunteers
- 250 people
- Sponsor
- University of Calgary
COVID-19
Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19
Patients with moderate to severe COVID-19 present a very high risk of thromboembolic disease.This multicenter, prospective, randomized, event-driven study evaluates rivaroxaban compared with standard of care with…
- Trial name
- COVID-PREVENT (NCT04416048)
- Testing
- Rivaroxaban, Standard Of Care (SOC)
- Where
- 24 sites in Germany
- Volunteers
- 111 people
- Sponsor
- Charite University, Berlin, Germany
Atrial Fibrillation, Stroke
DOAC in Chinese Patients With Atrial Fibrillation
Direct oral anticoagulants (DOACs) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF).
- Conditions
- Atrial Fibrillation, Stroke, Stroke, Acute, Brain Diseases
- Trial name
- DOAC-REAL (NCT05378035)
- Testing
- Blood Tests
- Where
- Hong Kong
- Volunteers
- 427 people
- Sponsor
- Chinese University of Hong Kong
Pulmonary Embolism
Effectiveness and Safety of Rivaroxaban Used in Extended Anticoagulation for Pulmonary Embolism Patients
Domestic and international guidelines for the management of pulmonary embolism have suggested that the standard duration of anticoagulation should cover at least 3 months.Whether extended anticogulation therapy shoud balance the…
- Trial name
- NCT04527042
- Testing
- Rivaroxaban
- Volunteers
- 496 people
- Sponsor
- China-Japan Friendship Hospital
Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
Patients with active cancer are ~5-fold more likely to develop a venous thromboembolism (VTE) than those without. When VTE occurs, cancer patients carry an up to a 3-fold higher rate of thrombosis recurrence and ~twice the risk…
- Trial name
- OSCAR-US (NCT04979780)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
- Where
- United States
- Volunteers
- 3,708 people
- Sponsor
- Bayer
Acute Kidney Injury
Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?
Anticoagulation-Related Nephropathy (ARN) is a side effect of treatment with blood thinners which leads to kidney dysfunction. A recent review suggests that kidney function should be assessed (by measuring serum creatinine)…
- Trial name
- NCT02900170
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Albert Einstein Healthcare Network
Atrial Fibrillation, Frailty
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
The objective of this study is to establish a near-real-time prospective monitoring program in Medicare, Optum and MarketScan Research data to evaluate the benefit of new cardiovascular disease (CVD) drugs for older adults with…
- Conditions
- Atrial Fibrillation, Frailty, Anticoagulant-induced Bleeding, Stroke
- Trial name
- NCT04878497
- Testing
- Warfarin, Dabigatran, Rivaroxaban
- Where
- United States
- Volunteers
- 1,000,000 people
- Sponsor
- Brigham and Women's Hospital
Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral)
Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation
Endothermal heat-induced thrombosis (EHIT) is a thrombotic complication specific to endovenous thermal ablation of the great saphenous vein (GSV), for which no prophylactic regimen is standardized.
- Conditions
- Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral), Varicose Veins Leg, Venous Thrombosis
- Trial name
- NCT07699796
- Testing
- Apixaban, Rivaroxaban
- Where
- United States
- Volunteers
- 564 people
- Sponsor
- Heart, Artery, and Vein Center of Fresno
Bleeding
A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
The purpose of this study is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Rivaroxaban.
- Trial name
- NCT02220725
- Testing
- Andexanet
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Ischemic Stroke
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
DO-IT is an international, prospective observational registry evaluating whether the administration of intravenous thrombolysis (IVT) is safe and improves functional outcome in ischemic stroke patients with recent direct oral…
- Trial name
- DO-IT Cohort (NCT06556446)
- Testing
- Tenecteplase and Alteplase
- Where
- 33 sites in Austria, Belgium and 13 more
- Volunteers
- 2,800 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Non-valvular Atrial Fibrillation (NVAF), Thromboembolism
Stepwise vs Standard Anticoagulation for AF Patients Undergoing CIED Implantation (STEP-AF)
This is a multi-center, prospective, open-label, randomized controlled trial (STEP-AF) designed to evaluate the safety of a stepwise anticoagulation strategy compared with the guideline-recommended standard anticoagulation…
- Conditions
- Non-valvular Atrial Fibrillation (NVAF), Thromboembolism, Cardiac Implantable Electronic Device, Perioperative Bleeding
- Trial name
- STEP-AF (NCT07616414)
- Testing
- Stepwise Anticoagulation Regimen, Standard Anticoagulation Regimen
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Atrial Fibrillation, Venous Thromboembolism
Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm
This study shall determine whether XAPPORT - a mobile device app based on different guidelines, the summary of product characteristics of rivaroxaban, and clinical facts and practice - provides adequate guidance to physicians…
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Pulmonary Embolism
- Trial name
- VeriXAPPORT (NCT02900404)
- Testing
- XAPPORT, Expert Panel ("gold standard")
- Sponsor
- Bayer